Key result
Tirofiban administration in high-risk patients with NSTE-ACS after PCI significantly reduced major adverse cardiac events (P<0.05) without increasing bleeding complications (P=0.1).
RCT (n=240)
p-value: p=<0.05
Supports tirofiban in high-risk NSTE-ACS post-PCI; reinforces GP IIb/IIIa inhibitor role without excess bleeding.
OBJECTIVE: To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI). METHODS: A total of 240 patients were randomized to either a tirofiban group or a control group. RESULTS: Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1). CONCLUSIONS: The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2009) conducted an RCT in Non-ST-segment elevation acute coronary syndromes (NSTE-ACS) (n=240). Tirofiban vs. Control group was evaluated on Major adverse cardiac events (MACE) (p=<0.05). Tirofiban administration in high-risk patients with NSTE-ACS after PCI significantly reduced major adverse cardiac events (P<0.05) without increasing bleeding complications (P=0.1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: